LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

LLY

806.87

-1.43%↓

JNJ

155.12

-1.13%↓

ABBV

190.75

+0.09%↑

NVO

76.95

-3.5%↓

UNH

307.68

-1.78%↓

Search

Anavex Life Sciences Corp

Fermé

SecteurSoins de santé

8.6 7.37

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.01

Max

8.61

Chiffres clés

By Trading Economics

Revenu

915K

-11M

BPA

-0.132

Employés

42

EBITDA

-779K

-13M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+254.92% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-21M

706M

Ouverture précédente

1.23

Clôture précédente

8.6

Sentiment de l'Actualité

By Acuity

50%

50%

142 / 381 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Anavex Life Sciences Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 juin 2025, 23:40 UTC

Acquisitions, Fusions, Rachats

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- 2nd Update

15 juin 2025, 23:27 UTC

Acquisitions, Fusions, Rachats

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- Update

15 juin 2025, 23:10 UTC

Acquisitions, Fusions, Rachats

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium

13 juin 2025, 22:33 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefonica Ecuador for $380 Million

15 juin 2025, 23:50 UTC

Market Talk

Gold Edges Higher Amid Likely Safe-Haven Demand -- Market Talk

15 juin 2025, 23:47 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over Middle East -- Market Talk

15 juin 2025, 23:41 UTC

Market Talk

Oil Rises Amid Middle East Tensions -- Market Talk

15 juin 2025, 23:33 UTC

Market Talk

China Most Affected by Any Disruption to Iran Crude Oil Exports -- Market Talk

15 juin 2025, 23:29 UTC

Market Talk

Oil Price Could Rise More This Week -- Market Talk

15 juin 2025, 23:27 UTC

Market Talk

Fed's Powell Likely to Emphasize Ongoing Policy Patience -- Market Talk

15 juin 2025, 23:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 juin 2025, 23:02 UTC

Market Talk

Global Energy Roundup: Market Talk

15 juin 2025, 23:02 UTC

Market Talk

Rising Middle East Tensions Could Be Passing Storm for World Economy -- Market Talk

15 juin 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

Santos Says Recommendation Requires Independent Expert Concluding Offer Is Fair, Reasonable

15 juin 2025, 22:47 UTC

Acquisitions, Fusions, Rachats

Santos Intends to Recommend Shareholders Vote In Favor of Transaction If Binding Offer Made

15 juin 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Santos Intends to Negotiate Terms of Process, Exclusivity Deed With XRG Consortium

15 juin 2025, 22:46 UTC

Acquisitions, Fusions, Rachats

Santos to Give XRG Consortium Due Diligence Access

15 juin 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Santos Says XRG Consortium Offer Is Final, Had Made Two Earlier Proposals

15 juin 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Santos Says XRG Consortium Offering A$8.89/Share in Cash

15 juin 2025, 22:44 UTC

Acquisitions, Fusions, Rachats

Santos Says XRG Consortium Includes Abu Dhabi Development Holding Co and Carlyle

15 juin 2025, 22:44 UTC

Acquisitions, Fusions, Rachats

Santos Gets Takeover Offer From Consortium Led by Abu Dhabi's Adnoc

15 juin 2025, 22:31 UTC

Market Talk

Gold Price Can Push Toward New All-Time High -- Market Talk

14 juin 2025, 01:24 UTC

Acquisitions, Fusions, Rachats

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 juin 2025, 23:50 UTC

Acquisitions, Fusions, Rachats

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 juin 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 juin 2025, 23:09 UTC

Acquisitions, Fusions, Rachats

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 juin 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 juin 2025, 22:18 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefonica Ecuador for $380M

13 juin 2025, 22:04 UTC

Market Talk
Acquisitions, Fusions, Rachats

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 juin 2025, 21:42 UTC

Acquisitions, Fusions, Rachats

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

Comparaison

Variation de prix

Anavex Life Sciences Corp prévision

Objectif de Prix

By TipRanks

254.92% hausse

Prévisions sur 12 Mois

Moyen 28.5 USD  254.92%

Haut 42 USD

Bas 15 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

8.275 / 9.312Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

142 / 381Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.